Do antidepressants improve negative symptoms in schizophrenia?

BMJ

Volumn 343, Issue 7814, 2011, Pages

  Barnes, Thomas R E ^a   Paton, Carol ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CHOLINESTERASE INHIBITOR; CLOZAPINE; GINKGO BILOBA EXTRACT; LAMOTRIGINE; MEMANTINE; MIRTAZAPINE; MODAFINIL; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; RISPERIDONE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR;

CLINICAL FEATURE; CLINICAL PRACTICE; COGNITIVE THERAPY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; ENVIRONMENTAL FACTOR; HUMAN; META ANALYSIS (TOPIC); MONOTHERAPY; NEGATIVE SYNDROME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SCHIZOPHRENIA; SOCIAL BEHAVIOR; UNCERTAINTY; ARTICLE; EVIDENCE BASED MEDICINE; PATHOPHYSIOLOGY;

ANTIDEPRESSIVE AGENTS; EVIDENCE-BASED MEDICINE; HUMANS; SCHIZOPHRENIA; UNCERTAINTY;

EID: 79960091215     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.d3371     Document Type: Review

References (26)

1. Buchanan RW. Persistent negative symptoms in schizophrenia: an overview. Schizophr Bull 2007;33:1013-22. (Pubitemid 47216643)
2. Bobes J, Arango C, Garcia-Garcia M, Rejas J, CLAMORS Study Collaborative Group. Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study. J Clin Psychiatry 2010;71:280-6.
3. Carpenter WT Jr, Heinrichs DW, Alphs LD. Treatment of negative symptoms. Schizophr Bull 1985;11:440-52. (Pubitemid 15036187)
4. Erhart SM, Marder SR, Carpenter WT. Treatment of schizophrenia negative symptoms: future prospects. Schizophr Bull 2006;32:234-7.
5. Hofer A, Baumgartner S, Edlinger M, Hummer M, Kemmler G, Rettenbacher MA, et al. Patient outcomes in schizophrenia I: correlates with sociodemographic variables, psychopathology, and side effects. Eur Psychiatry 2005;20:386-94. (Pubitemid 41318004)
6. Rosenheck R, Leslie D, Keefe R. Barriers to employment for people with schizophrenia. Am J Psychiatry 2006;163:411-7. (Pubitemid 44469382)
7. Buckley PF, Stahl SM. Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or cul-de-sac? Acta Psychiatr Scand 2007;115:93-100.
8. Barnes TRE, Schizophrenia Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2011;25: 567-620.
9. Silver H, Barash I, Aharon N, Kaplan A, Poyurovsky M. Fluvoxamine augmentation of antipsychotics improves negative symptoms in psychotic chronic schizophrenic patients: a placebo-controlled study. Int Clin Psychopharmacol 2000;15:257-61. (Pubitemid 30660960)
10. Mulholland C, Lynch G, King DJ, Cooper SJ. A double-blind, placebo-controlled trial of sertraline for depressive symptoms in patients with stable, chronic schizophrenia. J Psychopharmacol 2003;17:107-12. (Pubitemid 36373148)
11. Iancu I, Tschernihovsky E, Bodner E, Piconne AS, Lowengrub K. Escitalopram in the treatment of negative symptoms in patients with chronic schizophrenia: a randomized double-blind placebo-controlled trial. Psychiatry Res 2010;179:19-23.
12. Berk M, Gama CS, Sundram S, Hustig H, Koopowitz L, D'Souza R, et al. Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomised, placebo-controlled clinical trial. Hum Psychopharmacol 2009;24:233-8.
13. Abbasi SH, Behpournia H, Ghoreshi A, Salehi B, Raznahan M, Rezazadeh SA, et al. The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: a double-blind randomized placebo-controlled trial. Schizophr Res 2010;116:101-6.
14. Cho SJ, Yook K, Kim B, Choi TK, Lee KS, Kim YW, et al. Mirtazapine augmentation enhances cognitive and negative symptoms in schizophrenia patients treated with risperidone: a randomized controlled trial. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:208-11.
15. Tiihonen J, Wahlbeck K, Kiviniemi V. The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis. Schizophr Res 2009;109:10-4.
16. Paton C, Whittington C, Barnes TRE. Augmentation with a second antipsychotic in patients with schizophrenia who partially respond to clozapine: a meta-analysis. J Clin Psychopharmacology 2007;27:198-204. (Pubitemid 46594939)
17. Chang JS, Ahn Y-M, Park HJ, Lee KY, Kim SH, Kang UG, et al. Aripiprazole augmentation in clozapine treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2008;69:720-31. (Pubitemid 351838681)
18. Weiner E, Conley RR, Ball MP, Feldman S, Gold JM, Kelly DL, et al. Adjunctive risperidone for partially responsive people with schizophrenia treated with clozapine. Neuropsychopharmacology 2010;35:2274-83.
19. Rummel-Kluge C, Kissling W, Leucht S. Antidepressants for the negative symptoms of schizophrenia. Cochrane Database Syst Rev 2006;3:CD005581.
20. Sepehry AA, Potvin S, Elie R, Stip E. Selective serotonin reuptake inhibitor (SSRI) add-on therapy for the negative symptoms of schizophrenia: a meta-analysis. J Clin Psychiatry 2007;68:604-10. (Pubitemid 46663044)
21. Singh SP, Singh V, Kar N, Chan K. Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis. Br J Psychiatry 2010;197:174-9.
22. Lecrubier Y. Review: adding SSRIs to antipsychotics does not improve negative symptoms in people with schizophrenia. Evid Based Mental Health 2007;10:113.
23. Turkington D, Kingdon D, Rathod S, Hammond K, Pelton J, Mehta R. Outcomes of an effectiveness trial of cognitive-behavioural intervention by mental health nurses in schizophrenia. Br J Psychiatry 2006;189:36-40. (Pubitemid 44023328)
24. Turkington D, Sensky T, Scott J, Barnes TRE, Nur U, Siddle R, et al. A randomized controlled trial of cognitive-behavior therapy for persistent symptoms in schizophrenia: a five-year follow-up. Schizophr Res 2008;98:1-7. (Pubitemid 350245592)
25. Wykes T, Steel C, Everitt B, Tarrier N. Cognitive behavior therapy for schizophrenia: effect sizes, clinical models, and methodological rigor. Schizophr Bull 2008;34:523-37.
26. Melle I, Larsen TK, Haahr U, Friis S, Johannesen JO, Opjordsmoen S, et al. Prevention of negative symptom psychopathologies in first-episode schizophrenia: two-year effects of reducing the duration of untreated psychosis. Arch Gen Psychiatry 2008;65:634-40. (Pubitemid 351787234)